357 related articles for article (PubMed ID: 9891044)
1. Two polymorphic variants of wild-type p53 differ biochemically and biologically.
Thomas M; Kalita A; Labrecque S; Pim D; Banks L; Matlashewski G
Mol Cell Biol; 1999 Feb; 19(2):1092-100. PubMed ID: 9891044
[TBL] [Abstract][Full Text] [Related]
2. p53 codon 72 polymorphism and risk of cervical carcinoma in Korean women.
Baek WK; Cho JW; Suh SI; Suh MH; Shin DH; Cho CH; Lee TS; Cha SD
J Korean Med Sci; 2000 Feb; 15(1):65-7. PubMed ID: 10719811
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters.
Brady CS; Duggan-Keen MF; Davidson JA; Varley JM; Stern PL
J Gen Virol; 1999 Dec; 80 ( Pt 12)():3233-3240. PubMed ID: 10567656
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity.
Sedman SA; Hubbert NL; Vass WC; Lowy DR; Schiller JT
J Virol; 1992 Jul; 66(7):4201-8. PubMed ID: 1318401
[TBL] [Abstract][Full Text] [Related]
5. The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells.
Chen TM; Chen CA; Hsieh CY; Chang DY; Chen YH; Defendi V
Oncogene; 1993 Jun; 8(6):1511-8. PubMed ID: 8389030
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of different allelic variants of wild-type human p53.
Moreau F; Matlashewski G
Biochem Cell Biol; 1992; 70(10-11):1014-9. PubMed ID: 1297328
[TBL] [Abstract][Full Text] [Related]
7. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.
Crook T; Tidy JA; Vousden KH
Cell; 1991 Nov; 67(3):547-56. PubMed ID: 1657399
[TBL] [Abstract][Full Text] [Related]
8. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
Pim D; Massimi P; Banks L
Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
[TBL] [Abstract][Full Text] [Related]
9. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.
Park JS; Kim EJ; Lee JY; Sin HS; Namkoong SE; Um SJ
Int J Cancer; 2001 Mar; 91(6):822-7. PubMed ID: 11275986
[TBL] [Abstract][Full Text] [Related]
10. Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6.
Gardiol D; Banks L
J Gen Virol; 1998 Aug; 79 ( Pt 8)():1963-70. PubMed ID: 9714244
[TBL] [Abstract][Full Text] [Related]
11. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.
Storey A; Thomas M; Kalita A; Harwood C; Gardiol D; Mantovani F; Breuer J; Leigh IM; Matlashewski G; Banks L
Nature; 1998 May; 393(6682):229-34. PubMed ID: 9607760
[TBL] [Abstract][Full Text] [Related]
12. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
Pim D; Banks L
Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
[TBL] [Abstract][Full Text] [Related]
13. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53.
Hoppe-Seyler F; Butz K
J Virol; 1993 Jun; 67(6):3111-7. PubMed ID: 8388491
[TBL] [Abstract][Full Text] [Related]
14. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes.
Kawamata Y; Mitsuhashi A; Unno Y; Kado S; Shino Y; Uesugi K; Eguchi O; Ishii J; Seki K; Sekiya S; Shirasawa H
Int J Oncol; 2002 Sep; 21(3):561-7. PubMed ID: 12168100
[TBL] [Abstract][Full Text] [Related]
15. P53 codon 72Arg polymorphism is not a risk factor for carcinogenesis in the chinese.
Wang NM; Tsai CH; Yeh KT; Chen SJ; Chang JG
Int J Mol Med; 1999 Sep; 4(3):249-52. PubMed ID: 10425273
[TBL] [Abstract][Full Text] [Related]
16. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
Scheffner M; Werness BA; Huibregtse JM; Levine AJ; Howley PM
Cell; 1990 Dec; 63(6):1129-36. PubMed ID: 2175676
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation.
Thomas M; Matlashewski G; Pim D; Banks L
Oncogene; 1996 Jul; 13(2):265-73. PubMed ID: 8710365
[TBL] [Abstract][Full Text] [Related]
18. The role of the E6-p53 interaction in the molecular pathogenesis of HPV.
Thomas M; Pim D; Banks L
Oncogene; 1999 Dec; 18(53):7690-700. PubMed ID: 10618709
[TBL] [Abstract][Full Text] [Related]
19. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins.
Scheffner M; Takahashi T; Huibregtse JM; Minna JD; Howley PM
J Virol; 1992 Aug; 66(8):5100-5. PubMed ID: 1321290
[TBL] [Abstract][Full Text] [Related]
20. Phylogenetic and functional analysis of sequence variation of human papillomavirus type 31 E6 and E7 oncoproteins.
Ferenczi A; Gyöngyösi E; Szalmás A; László B; Kónya J; Veress G
Infect Genet Evol; 2016 Sep; 43():94-100. PubMed ID: 27197052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
